High frequency of HLA-B44 allelic losses in human solid tumors.

[1]  D. Geraghty,et al.  Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.

[2]  F. Garrido,et al.  Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 , 2002, Cancer Immunology, Immunotherapy.

[3]  D. Jäger,et al.  Clinical cancer vaccine trials. , 2002, Current opinion in immunology.

[4]  C. Lutz,et al.  Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules , 2002, Immunogenetics.

[5]  H. Schreiber,et al.  Immunodominance and tumor escape. , 2002, Seminars in cancer biology.

[6]  U. Ritz,et al.  Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. , 2001, International journal of oncology.

[7]  J. Shabanowitz,et al.  Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors1 , 2001, The Journal of Immunology.

[8]  M. Ikeda,et al.  High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. , 2001, Biochemical and biophysical research communications.

[9]  P. Stern,et al.  A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells , 2000, Immunogenetics.

[10]  F. Garrido,et al.  Molecular strategies to define HLA haplotype loss in microdissected tumor cells. , 2000, Human immunology.

[11]  F. Garrido,et al.  Criteria to define HLA haplotype loss in human solid tumors. , 2000, Tissue antigens.

[12]  J. McCluskey,et al.  Distinct Functions of Tapasin Revealed by Polymorphism in MHC Class I Peptide Loading1 , 2000, The Journal of Immunology.

[13]  F. Foury,et al.  Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. , 1999, Cancer research.

[14]  C. Figdor,et al.  A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia , 1999, The Journal of experimental medicine.

[15]  A. Sewell,et al.  HLA‐A*0201 presents TAP‐dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin , 1998, European journal of immunology.

[16]  B. Seliger,et al.  Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. , 1998, Cancer research.

[17]  A. Nouri,et al.  Relevance of the immune system in human urological malignancies: prospective for future clinical treatments. , 1998, Urology.

[18]  P. Cresswell,et al.  HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. , 1998, Immunity.

[19]  C. Meijer,et al.  Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression , 1998, The Lancet.

[20]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[21]  R. Tampé,et al.  A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. , 1997, Science.

[22]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[23]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[24]  P. van Endert,et al.  Characterization of antigenic peptides presented by HLA‐B44 molecules on tumor cells expressing the gene MAGE‐3 , 1996, International journal of cancer.

[25]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.

[26]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive breast carcinomas. , 1996, Human immunology.

[27]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[28]  P. Stern,et al.  The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer , 1995, Nature Medicine.

[29]  X. Sastre,et al.  Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.

[30]  A. Harris,et al.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. , 1994, The American journal of pathology.

[31]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[32]  J. Bodmer,et al.  Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms , 1993, Annals of the New York Academy of Sciences.

[33]  F. Esteban,et al.  Presence of hpv 16 sequences in laryngeal carcinomas , 1990, International journal of cancer.

[34]  R. Versteeg,et al.  c‐myc down‐regulates class I HLA expression in human melanomas. , 1988, The EMBO journal.

[35]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[36]  J. Hors,et al.  HLA and cancer. , 1984, Transplantation proceedings.

[37]  P. Romero,et al.  A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 , 2005, Immunogenetics.

[38]  S. Rodríguez de Córdoba,et al.  HLA antigens in a sample of the Spanish population: Common features among Spaniards, Basques, and Sardinians , 2004, Human Genetics.

[39]  F. Garrido,et al.  Analysis of HLA expression in human tumor tissues , 2002, Cancer Immunology, Immunotherapy.

[40]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.

[41]  F. Garrido,et al.  Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants , 2001, International Journal of Cancer.

[42]  H. Inoko,et al.  New polymorphic microsatellite markers in the human MHC class I region. , 1999, Tissue antigens.

[43]  Ian Tomlinson,et al.  Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog , 1999, Nature medicine.

[44]  R. Rees,et al.  An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. , 1997, British Journal of Cancer.

[45]  Dominique Charron,et al.  HLA : genetic diversity of HLA functional and medical implication , 1997 .

[46]  A. Hill,et al.  MHC loss in colorectal tumours: evidence for immunoselection? , 1992, Cancer surveys.